A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

2024-516351-40-00 Protocol 70218902EDI1001 Human pharmacology (Phase I) - First administration to humans Ended

Start 15 Jul 2020 · End 17 Sep 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 70218902EDI1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 2
Countries 1
Sites 1

Metastatic Castration-Resistant Prostate Cancer

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Jul 2020 → 17 Sep 2025
Decision date (initial)
2024-09-16
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516351-40-00
EudraCT number
2019-004885-16

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic Castration-Resistant Prostate Cancer

VersionLevelCodeTermSystem organ class
21.1 LLT 10076506 Castration-resistant prostate cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 1 1
Rest of world
Israel
1

Investigational sites

Spain

1 site · Ended
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2020-07-15 2025-09-16 2020-07-15 2022-07-12

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-04 Spain Acceptable with conditions
2024-09-16
2024-09-16